Peter Zhang: Is Canada Ready for the Gene Therapy Era?
Peter Zhang, Director, Business Acceleration at Odaia, shared a post on LinkedIn:
”My latest in The Hill Times on gene therapies, and whether the Canadian healthcare system is ready for these innovative medicines.
When I was a board member with Hemophilia Ontario (now known as Bleeding Disorders Ontario), I was excited to hear about its patient impact firsthand.
This year, a Canadian with severe hemophilia B received the first gene therapy approved in Canada. But a single dose can cost more than $4 million, and payers need to approach patient access in an equitable and sustainable manner.
Canada also needs to consider its strategy for future innovations in gene therapy and it’s encouraging that there is ongoing work to leverage this technology to introduce therapies for patients living with Huntington’s disease, spinal muscular atrophy, and inherited retinal diseases.”
Stay updated with Hemostasis Today.
-
Aug 23, 2026, 17:51Gurpreet Kaurr: A Proud Milestone in Haematology and Oncology
-
Aug 23, 2026, 17:33Kathrine Kaspersen: How Voluntary Plasma Donors Helped Transform Denmark’s Plasma Supply
-
Aug 23, 2026, 16:51Sthanu Subramanian: Empagliflozin and a Rise in Hematocrit
-
Aug 23, 2026, 16:50Lale Tokgözoğlu: New PCSK9i Research Published in the European Heart Journal
-
Aug 23, 2026, 16:44Eric Gehrie: Your 2026 Guide to the Essentials of Transfusion Medicine
-
Aug 23, 2026, 16:35Thomas Dayspring: The Overlooked Pathway in Cholesterol Homeostasis
-
Aug 23, 2026, 16:28Evan Mapelu: The People Who Make Cancer Care Meaningful
-
Aug 23, 2026, 16:09Felice Gragnano: New Publication on Aspirin Discontinuation After PCI for Acute Coronary Syndromes
-
Aug 23, 2026, 16:06Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia